Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1-3 breast cancer after neoadjuvant systemic therapy, Multicenter Cohort Study

Abstract

Abstract Background This study investigated the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) in patients with initially high nodal burden. Methods In the multicenter retrospective cohort, 388 individuals with cN1-3 breast cancer who underwent NAST and had SLNB followed by completion axillary lymph node dissection (ALND) were included. In an external validation cohort, 267 patients with HER2+ or triple-negative breast cancer (TNBC) meeting similar inclusion criteria were included. Primary outcome was the false-negative rates (FNRs) of SLNB according to the MRI response and subtypes. We defined complete MRI responders as patients who experienced disappearance of suspicious features in the breast and axilla after NAST. Results. In the multicenter retrospective cohort (n = 388), 130 (33.5%) patients were cN2-3, while 55 (14.2%) showed complete MRI responses. In hormone receptor-positive HER2- (n=207), complete and non-complete responders had a high FNRs (31.3% [95% CI, 8.6–54.0] and 20.9% [95% CI, 14.1–27.6], respectively). However, in HER2+ or TNBC (n=181), the FNR of complete MRI responders was 0% (95% CI, 0–0), whereas that of non-complete responders was 33.3% (95% CI, 20.8–45.9). When we validated our findings in the external cohort with HER2+ or TNBC (n = 267), of which 34.2% were cN2-3, the FNRs of complete were 7.1% (95% CI, 0–16.7). Conclusions Our findings suggest that SLNB can be a reliable option for nodal status evaluation in selected patients who have responded well to NAST, especially in HER2+ and TNBC patients who show a complete MRI response.